Results 81 to 90 of about 35,569 (305)

The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]

, 2016
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Dods, RL, Donnelly, D
core   +1 more source

The Endothelial CXCR Family in Vascular Health and Disease

iNew Medicine, EarlyView.
ABSTRACT Endothelial cells (ECs) form the dynamic interface between blood and tissue, serving as key regulators of vascular homeostasis, inflammation, and repair. Among the molecular systems governing endothelial behavior, the C‐X‐C motif chemokine receptor (CXCR) family—originally characterized in immunology for its roles in leukocyte trafficking and ...
Zhiming Wu, Yandi Wu, Suowen Xu, Yu Huang, Li Wang   +4 more
wiley   +1 more source

Targeting GLP-1 receptor trafficking to improve agonist efficacy

Nature Communications, 2018
Glucagon-like peptide-1 receptor (GLP-1R) promotes insulin secretion from pancreatic beta cells and undergoes agonist-mediated endocytosis. Here, authors study GLP-1R endocytosis caused by different agonists and show that a longer plasma membrane ...
Ben Jones, Teresa Buenaventura, Nisha Kanda, Pauline Chabosseau, Bryn M. Owen, Rebecca Scott, Robert Goldin, Napat Angkathunyakul, Ivan R. Corrêa Jr, Domenico Bosco, Paul R. Johnson, Lorenzo Piemonti, Piero Marchetti, A. M. James Shapiro, Blake J. Cochran, Aylin C. Hanyaloglu, Asuka Inoue, Tricia Tan, Guy A. Rutter, Alejandra Tomas, Stephen R. Bloom   +20 more
doaj   +1 more source

Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia

, 2015
Ofer Yanay,1,2 Adam L Bailey,3 Kelly Kernan,1 Jerry J Zimmerman,1,2 William R Osborne1 1Department of Pediatrics, University of Washington, 2Division of Pediatric Critical Care Medicine, Seattle Children's Hospital, Seattle, WA, 3Medical Scientist ...
Osborne WR, Yanay O, Bailey AL, Zimmerman JJ, Kernan K   +4 more
core  

Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s)

, 2007
Udgivelsesdato: 2007-JulThe glucagon-like peptide (GLP)-1 receptor is a promising target for the treatment of type 2 diabetes and obesity, and there is great interest in characterizing the pharmacology of the GLP-1 receptor and its ligands.
Jorgensen, Rasmus, Vrecl, Milka, Schwartz, Thue W, Elling, Christian E, Kubale, Valentina   +4 more
core   +1 more source

cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist

, 2021
Aim: The effect of the weekly exendin-based glucagon-like peptide-1 receptor agonist efpeglenatide on cardiovascular (CV) outcomes in high-risk patients with type 2 diabetes (T2DM) with and without chronic kidney disease (CKD) is unknown.
Laura Heenan, Branch, Kelley, Rosenstock, Julio, Khurmi, Nardev S., Sattar, Naveed, Lam, Carolyn S.P., Stefano Del Prato, Del Prato, Stefano, Kelley Branch, Gerstein, Hertzel C., Carolyn S. P. Lam, Naveed Sattar, Hertzel C. Gerstein, Pratley, Richard, Richard Pratley, Heenan, Laura, Julio Rosenstock, Nardev S. Khurmi   +17 more
core   +1 more source

Standardized MRI‐Based Quantification of Epicardial Adipose Tissue Volume: Reproducibility and Agreement With Cardiac Computed Tomography

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Epicardial adipose tissue volume (EATV) is increasingly recognized as a cardiometabolic risk marker associated with adverse outcomes. The most established approach for EATV quantification is cardiac computed tomography (CT). MRI offers a radiation‐free alternative allowing simultaneous assessment of myocardial function and tissue ...
Judith Gronwald, Svante S. Gersch, Zoé Böttiger, Clara Hagedorn, Torben Lange, Sören J. Backhaus, Sebastian Kelle, Constanze Schmidt, Karl Toischer, Andreas Schuster, Alexander Schulz   +10 more
wiley   +1 more source

Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists

Diabetes & Metabolism
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, secreted from gut endocrine cells, which acts to potentiate nutrient-induced insulin secretion. Activation of its receptor, GLP-1R, decreases glucagon secretion and gastric emptying, thereby decreasing blood glucose and body weight. It is largely through these mechanisms that Glucagon-like peptide-
J Chen, ME Cooper, MT Coughlan
openaire   +2 more sources

Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?

Introduction Parkinson’s disease (PD) is a common neurodegenerative disease. Glucagon-like peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD and are being considered for the treatment of PD.
Doggrell, Sheila A
core   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source